1 active not recruiting, 1 completed, 1 not yet recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis RO7845860 - Relapsing Multiple Sclerosis | Phase 1 | Not yet recruiting | Hoffmann-La Roche | 85 | 2026-11-23 | 2026-10-09 |
| An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis rapcabtagene autoleucel (YTB323) - Relapsing Multiple Sclerosis | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 28 | 2025-02-24 | 2026-09-02 |
| CDP323 Biomarker Study CDP323, Placebo - Relapsing Multiple Sclerosis | Phase 1 / Phase 2 | Completed | UCB Pharma | 71 | 2008-07-01 | 2011-09-12 |
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Nervous System Diseases (1)
CDP323 (1)
Hoffmann-La Roche (1) · Novartis Pharmaceuticals (1) · UCB Pharma (1)
Australia (1) · France (1) · Germany (1) · Italy (1) · Spain (1) · Switzerland (1) · United Kingdom (1)